Composition for improving mental health problems
Bifidobacterium longum subsp. infantis bacteria in food or drink products address the need for safe, daily mental health disorder treatment by improving mental health scores and altering intestinal flora composition.
Patent Information
- Application Number
- JP2019501419
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2017-02-24
- Filing Date
- 2018-02-22
- Publication Date
- 2024-12-05
- Estimated Expiration
- 2038-02-22
AI Technical Summary
There is a need for a safe and effective daily treatment for mental health disorders that does not have side effects, as chemically synthesized drugs are not suitable for long-term use.
A composition containing Bifidobacterium longum subsp. infantis bacteria, specifically strains BCCM LMG23728 or M-63, is used as an active ingredient to improve mental health disorders, which can be incorporated into food or drink products.
The Bifidobacterium longum subsp. infantis bacteria effectively improve mental health disorders without side effects, as demonstrated by increased mental health scores in subjects, particularly in mental health (MH) and mental health level (MCS) as measured by SF-36, and alter the intestinal flora composition.
Smart Images

Figure 0007594855000002 
Figure 0007594855000003 
Figure 0007594855000004
Abstract
Description
[Technical field]
[0001] The present invention relates to an agent or composition for improving mental health disorders, and a food and drink composition for improving mental health disorders. [Background technology]
[0002] In recent years, due to various stresses caused by diversification of living and working environments, complicated human relationships, and the like, people living in modern society often have poor mental health (mental health, mental hygiene) even if they are not in a state that leads to illnesses such as mental disorders. In addition, due to an increase in natural disasters, the number of cases in which victims are forced to suddenly change their living environment and suffer from mental health problems (mental health problems) is also increasing. If such mental health problems continue for a long period of time, they may develop into physical health problems or mental disorders. If a mental disorder such as depression develops, drug treatment with side effects may be required for a long period of time, so it is necessary to properly care for mental health problems so that mental disorders do not develop. However, it is not appropriate to use chemically synthesized drugs such as tranquilizers that have side effects in order to care for mental health problems on a daily basis. Therefore, there is a demand for medicines or foods and beverages that are effective in improving mental health problems that can be easily taken on a daily basis and have no side effects, preferably before the onset of a mental disorder such as depression.
[0003] Regarding the improvement of mental health problems, Patent Document 1 discloses a psychological condition improving agent that contains isoalpha acid or reduced isoalpha acid as an active ingredient, as a psychological condition improving agent that improves mood and relieves psychological tension, thereby increasing a sense of comfort. Patent Document 2 discloses a mood improver that contains turmeric extract and improves the deterioration of mood, a phenomenon that occurs as a result of a complex combination of physical fatigue and mental stress.
[0004] On the other hand, bifidobacteria and lactic acid bacteria are known to have useful effects such as intestinal regulation as probiotics. In recent years, it has been known that the intestinal environment is involved in signal transmission from the intestine to the brain (brain-gut correlation), and probiotics are known to affect brain function by interacting with the intestinal flora. For example, Non-Patent Document 1 discloses that anxiety symptoms were improved in patients with chronic fatigue syndrome (CFS) by taking Lactobacillus casei Shirota strain. Furthermore, Patent Document 3 discloses a method for treating depression and diseases characterized by hypothalamus-pituitary-adrenal axis hypersensitivity by administering probiotics such as Lactobacillus bacteria and Bifidobacterium bacteria.
[0005] As described above, the effectiveness of ingesting probiotics for mental disorders such as depression has already been reported, but it is known that probiotics have different physiological effects depending on the species. Furthermore, it is not known that Bifidobacterium longum subsp. infantis BCCM LMG23728 is useful for improving mental health disorders. [Prior art documents] [Patent documents]
[0006] [Patent Document 1] JP 2010-209022 A [Patent Document 2] JP 2016-199491 A [Patent Document 3] Special Publication No. 2006-525313 [Non-patent literature]
[0007] [Non-Patent Document 1] A Venket Rao et al., Gut Pathog., (2009)1:6 Summary of the Invention [Problem to be solved by the invention]
[0008] The present invention has been made in consideration of the above circumstances, and an objective of the present invention is to provide an agent or composition for improving mental health disorders, which is effective in improving mental health disorders and is highly safe that can be taken continuously on a daily basis, and a food and beverage composition for improving mental health disorders. [Means for solving the problem]
[0009] As a result of intensive research to solve the above problems, the present inventors discovered that bacteria belonging to Bifidobacterium longum subsp. infantis have the effect of improving mental health disorders through changes in the intestinal flora, and thus completed the present invention.
[0010] That is, the present invention is an agent or composition for improving mental health disorders, which comprises, as an active ingredient, a bacterium belonging to Bifidobacterium longum subsp. infantis. In a preferred embodiment of the mental health disorder improving agent or composition for improving mental health disorders, the bacterium is Bifidobacterium longum subsp. infantis BCCM LMG23728 or Bifidobacterium longum subsp. infantis M-63 (NITE BP-02623). In a preferred embodiment of the agent or composition for improving a mental health disorder, the mental health disorder is one evaluated using SF-36. Furthermore, in a preferred embodiment of the agent or composition for improving mental health disorders, the mental health disorder is a state in which the mental health disorder is low in the mental health (MH) and / or mental health status (MCS) score.
[0011] Furthermore, the present invention provides a food and drink composition for improving mental health disorders, which contains, as an active ingredient, a bacterium belonging to Bifidobacterium longum subsp. infantis. In a preferred embodiment of the food and drink composition for improving mental health disorders, the bacterium is Bifidobacterium longum subsp. infantis BCCM LMG23728 or Bifidobacterium longum subsp. infantis M-63 (NITE BP-02623). Effect of the Invention
[0012] According to the present invention, a means for effectively improving mental health disorders is provided. Specifically, it is possible to provide an agent or composition for improving mental health disorders, and a food and drink composition for improving mental health disorders, which are effective in improving mental health disorders and can be continuously ingested on a daily basis and are highly safe. In addition, the bacteria belonging to Bifidobacterium longum subsp. infantis used in the present invention are naturally present in the intestinal flora of mammals, are highly safe for the body and have no risk of side effects, and are useful as medicines or foods and beverages. [Brief description of the drawings]
[0013] [Figure 1] A graph showing the change in SF-36 "Mental Health (MH)" score between the Bifidobacterium longum subsp. infantis BCCM LMG23728 intake group and the non-intake group. [Diagram 2] A graph showing the change in SF-36 "Mental Health Score (MCS)" score between the Bifidobacterium longum subsp. infantis BCCM LMG23728 intake group and the non-intake group. [Diagram 3] This graph shows the SF-36 "Mental Health (MH)" scores on the final day of the study for the Bifidobacterium longum subsp. infantis BCCM LMG23728 intake group and the non-take group. [Figure 4] This graph shows the SF-36 "Mental Health Score (MCS)" scores on the final day of the study for the Bifidobacterium longum subsp. infantis BCCM LMG23728 intake group and the non-take group. [Diagram 5] This graph shows the percentage of bacteria belonging to the Bacteroidetes phylum in the intestinal flora after the end of the study in the Bifidobacterium longum subsp. infantis BCCM LMG23728 intake group and the non-intake group. [Figure 6] This graph shows the percentage of bacteria belonging to the Firmicutes phylum in the intestinal flora after the end of the study in the Bifidobacterium longum subsp. infantis BCCM LMG23728 intake group and the non-intake group. [Figure 7] This graph shows the composition ratio of bacteria belonging to the Firmicutes phylum to bacteria belonging to the Bacteroidetes phylum in the intestinal flora after the end of the study for the group that took Bifidobacterium longum subsp. infantis BCCM LMG23728 and the group that did not take it (occupancy rate of bacteria belonging to the Firmicutes phylum / occupancy rate of bacteria belonging to the Bacteroidetes phylum). [Figure 8] A graph showing the correlation between the SF-36 "Mental Health Score (MCS)" score in the group taking Bifidobacterium longum subsp. infantis BCCM LMG23728 and the composition ratio of bacteria belonging to the Firmicutes phylum to bacteria belonging to the Bacteroidetes phylum in the intestinal flora (occupancy rate of bacteria belonging to the Firmicutes phylum / occupancy rate of bacteria belonging to the Bacteroidetes phylum). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0014] Next, an embodiment of the present invention will be described. However, the present invention is not limited to the following embodiment, and can be freely modified within the scope of the present invention.
[0015] The agent for improving mental health disorders of the present invention contains a bacterium belonging to Bifidobacterium longum subsp. infantis as an active ingredient. The agent for improving mental health disorders of the present invention contains a bacterium belonging to Bifidobacterium longum subsp. infantis as an active ingredient, and does not preclude the inclusion of other ingredients. That is, the agent for improving mental health disorders of the present invention is equivalent to a composition for improving mental health disorders. Therefore, another aspect of the present invention is a composition for improving mental health disorders containing a bacterium belonging to Bifidobacterium longum subsp. infantis as an active ingredient.
[0016] "Mental health" in this invention is defined by the World Health Organization (WHO) in 2007, and is an example of a Japanese translation of the definition: "A state of complete well-being in which an individual is able to realize his or her own potential, to cope with the normal stresses of life, to work productively and fruitfully, and to contribute to his or her community."
[0017] In the present invention, the term "mental health problems" refers to a state in which the above-mentioned conditions are impaired in the subject, for example, a nervous psychological state, a depressed mood, or a gloomy mood state in the subject. In the present invention, "improvement of mental health deficiencies" refers to the improvement of the above-mentioned "mental health deficiencies" and refers to a state in which "mental health" is no longer impaired. For example, this can include a case in which a nervous psychological state, a depressed state or a gloomy mood state in a subject is alleviated, improved or resolved, or a case in which it is determined that the subject has become in a calm or happy mood state. Whether or not there is a mental health disorder, and whether or not the mental health disorder has improved, may be a subjective judgment by the person concerned, or an objective judgment by a doctor or the like, but it is preferable that the assessment be made using an objective measure such as a psychological test.
[0018] The present invention is applicable to people who suffer from mental health problems or who need improvement in their mental health, but who do not suffer from a mental disorder or illness. Whether or not improvement in mental health problems is needed may be a subjective judgment by the person to whom the invention is applied, or an objective judgment by a doctor or the like.
[0019] Examples of mental disorders and mental illnesses include depression, bipolar disorder (manic depression), and schizophrenia. Among these, whether or not a person suffers from depression can be diagnosed by, for example, optical topography (registered trademark) or a blood test. Therefore, the present invention can be applied to people who have not been diagnosed with depression by these tests. In the case of a blood test, depression is diagnosed when the ethanolamine phosphate concentration in plasma is 1.5 μM or less, so that the present invention is applied to people whose ethanolamine phosphate concentration in plasma is preferably more than 1.5 μM, more preferably 2.0 μM or more, and even more preferably 2.5 μM or more. On the other hand, the upper limit of the concentration is not particularly limited, but is preferably 5.0 μM or less, more preferably 4.0 μM or less, and even more preferably 3.0 μM or less. As for other mental disorders and illnesses, whether or not a person suffers from them can be diagnosed by known methods.
[0020] Therefore, it is preferable that the agent or composition for improving mental health disorders of the present invention is not used for the treatment of the above-mentioned mental disorders or mental diseases, and in fact the mental health disorders improved by the present invention are different from the above-mentioned mental disorders or mental diseases.
[0021] The present invention is preferably applied to victims of natural disasters such as earthquakes, floods, tsunamis, etc. When a natural disaster occurs, a large number of victims appear at once, and the mental health status of each victim varies greatly, so that such victims require a completely different approach than that for patients with normal mental disorders. Furthermore, such victims must deal with various stresses such as physical injuries, damage to land and buildings, and moving to temporary housing, and even if each stress is minor, the accumulation of such stresses can lead to a condition called Dripping Faucet Syndrome, which causes a sense of irritability, social withdrawal, anhedonia, etc. Therefore, the "subject" in the present invention is more preferably a human suffering from Dripping Faucet Syndrome.
[0022] When "mental health problems" in the present invention are evaluated by objective measures such as psychological tests, examples of such psychological tests include the SF-36 (MOS 36-Item Short-Form Health Survey), etc. SF-36 is a registered trademark of the Medical Outcomes Trust.
[0023] The SF-36 is a scale that evaluates health-related QOL (HRQOL) based on the scores of 36 questions categorized into eight categories: "Physical Functioning (PF)", "Role Physical (RP)", "Bodily Pain (BP)", "General Health Perception (GH)", "Vitality (VT)", "Social Functioning (SF)", "Role Emotional (RE)" and "Mental Health (MH)". The higher the overall score, the better the QOL is evaluated. The SF-36 is a scientific, reliable and valid scale for measuring health-related QOL, which was created in the United States and is widely used internationally. Furthermore, in the SF-36, the eight items are classified into two categories, physical and mental, and QOL can be evaluated from two aspects: the physical aspect QOL summary score (Physical Component Summary; PCS) and the mental aspect QOL summary score (Mental Component Summary; MCS) (Journal of the Japanese Society of Low Back Pain, Vol. 8, No. 1, pp. 38-43, 2002). In this specification, when referring to "Mental Health (MH)," it will be written as "Mental Health (MH)," "Mental Health (MH)," "Mental Health," "Mental Health," "MH," etc. This also applies to other items.
[0024] When "mental health problems" in the present invention are evaluated by SF-36, a low score for "mental health (MH)" and / or "mental health score (MCS)" is preferred. In this case, the "mental health (MH)" score is preferably 70 or less, more preferably 60 or less, and even more preferably 50 or less. The "mental health score (MCS)" score is preferably 50 or less, more preferably 40 or less, and even more preferably 30 or less. Furthermore, when "improvement of mental health deficiencies" in the present invention is evaluated as having improved, the improvement is evaluated as occurring when the scores for "mental health (MH)" and / or "mental health score (MCS)" increase. Although the mental health problems improved by the present invention are different from mental disorders such as depression, bipolar disorder (manic depression) and schizophrenia, in the case of suffering from these mental disorders, the scores of SF-36 other than "Mental Health (MH)" and "Mental Health Score (MCS)" are generally low. For example, in the case of a patient suffering from these mental disorders, the score of "Physical Functioning (PF)" is preferably 70 or less, more preferably 60 or less. In addition, the score of "Role Functioning (Physical) (RP)" is preferably 70 or less, more preferably 60 or less. The score of "Bodily Pain (BP)" is preferably 80 or less, more preferably 70 or less. The score of "General Health (GH)" is preferably 60 or less, more preferably 50 or less. The score of "Vitality (VT)" is preferably 60 or less, more preferably 50 or less. The score of "Social Functioning (SF)" is preferably 80 or less, more preferably 70 or less. Furthermore, the "role functioning (mental) (RE)" score is preferably 80 or less, more preferably 70 or less. Additionally, the "physical health status (PCS)" score is preferably 50 or less, more preferably 40 or less.
[0025] As the bacterium belonging to Bifidobacterium longum subsp. infantis used in the present invention, one or more types of bacteria belonging to known Bifidobacterium longum subsp. infantis can be freely selected and used as long as the effects of the present invention are not impaired. Among them, in the present invention, Bifidobacterium longum subsp. infantis BCCM LMG23728 is a preferred embodiment. Note that Bifidobacterium longum subsp. infantis used in the present invention may also be simply referred to as Bifidobacterium infantis.
[0026] Bifidobacterium longum subsp. infantis BCCM LMG23728 is available from the Belgian Coordinated Collections of Microorganisms (BCCM), the Belgian collection centre, 8, Scionsrue (Wuertenskap), B-1000 Brussels, Belgium. In addition, Bifidobacterium longum subsp. infantis BCCM LMG23728 is the same bacterium as Bifidobacterium longum subsp. infantis M-63 (NITE BP-02623), and in the preferred embodiment, either bacterium may be used. Bifidobacterium longum subsp. infantis M-63 (NITE BP-02623) was internationally deposited under the Budapest Treaty on January 26, 2018 at the National Institute of Technology and Evaluation, Patent Microorganisms Deposit Center (Room 122, 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, 292-0818) under the accession number of NITE BP-02623. In addition, in this specification, "the same bacterium" refers to a bacterium of the same genus or species as the deposited bacterium, whose nucleotide sequence of the 16SrRNA gene has a homology of 98% or more, preferably 99% or more, and more preferably 100%, to the nucleotide sequence of the 16SrRNA gene of the bacterium, and preferably has the same bacteriological properties as the bacterium. Furthermore, the bacterium or the same bacterium may be a bacterium bred from these bacteria by mutation treatment, genetic recombination, selection of natural mutant strains, or the like, so long as the effects of the present invention are not impaired.
[0027] The bacteria belonging to Bifidobacterium longum subsp. infantis of the present invention can be easily grown by culturing them. The method for culturing the bacteria belonging to Bifidobacterium longum subsp. infantis of the present invention is not particularly limited as long as the bacteria can grow, and a method commonly used for culturing the bacteria can be used with appropriate modifications as necessary. For example, the culture temperature may be 25 to 50°C, and preferably 30 to 40°C. The culture is preferably performed under anaerobic conditions, and for example, the culture can be performed while aerating anaerobic gas such as carbon dioxide gas.
[0028] The medium for culturing the bacteria belonging to Bifidobacterium longum subsp. infantis is not particularly limited, and a medium generally used for culturing the bacteria can be used by appropriately modifying it as necessary. As the carbon source of the medium, for example, sugars such as galactose, glucose, fructose, mannose, cellobiose, maltose, lactose, sucrose, trehalose, starch, starch hydrolysate, blackstrap molasses, etc. can be used depending on the assimilation. As the nitrogen source of the medium, for example, ammonium salts such as ammonia, ammonium sulfate, ammonium chloride, ammonium nitrate, and nitrates can be used. In addition, as the inorganic salt of the medium, for example, sodium chloride, potassium chloride, potassium phosphate, magnesium sulfate, calcium chloride, calcium nitrate, manganese chloride, ferrous sulfate, etc. can be used. In addition, organic components such as peptone, soybean flour, defatted soybean meal, meat extract, yeast extract, etc. may be used in the medium. In addition, as the medium, for example, MRS medium can be suitably used as a prepared medium.
[0029] After culturing the bacteria belonging to Bifidobacterium longum subsp. infantis of the present invention, the obtained culture may be used as it is, or may be used after dilution or concentration, or the bacterial cells recovered from the culture may be used. The bacteria may be live or dead, or may be both live and dead, but live bacteria are preferred. In addition, various additional procedures such as heating and freeze-drying can be carried out after the culture, so long as the efficacy of the present invention is not impaired. It is preferable that the additional procedures are those that ensure high survival of live bacteria.
[0030] When the subject of application ingests the mental health deficiency improving agent or composition for improving mental health deficiency of the present invention, the mental health deficiency of the subject of application is improved. The bacterium belonging to Bifidobacterium longum subsp. infantis used as an active ingredient in the mental health deficiency improving agent or composition for improving mental health deficiency of the present invention has been used in foods and medicines for many years, and exists as a good bacterium in the intestines of animals, so it is expected to be highly safe to the living body. Therefore, it is considered that side effects and dependency are unlikely to occur, so it can be taken continuously for a long period of time, and the subject of application can take it easily. The mental health deficiency improving agent or composition for improving mental health deficiency of the present invention can be taken daily in the form of a medicine or food and drink, so it can be used as a medicine for improving mental health deficiency or a food and drink composition for improving mental health deficiency.
[0031] <Medicine> The medicine for improving mental health disorders of the present invention is not particularly limited as long as it contains a bacterium belonging to Bifidobacterium longum subsp. infantis. The medicine for improving mental health disorders of the present invention may use a bacterium belonging to Bifidobacterium longum subsp. infantis as it is, or may be formulated by mixing with a physiologically acceptable liquid or pharmaceutical carrier.
[0032] The dosage form of the medicament for improving mental health failure of the present invention is not particularly limited, and it can be formulated into solid preparations such as powders, granules, tablets, capsules, etc.; liquid preparations such as solutions, syrups, suspensions, emulsions, etc.; suppositories, ointments, etc. In the formulation, pharmaceutical carriers used in normal formulations can be used. In addition, the medicament for improving mental health failure of the present invention can also contain a component that has a known or future discovered effect of improving mental health failure.
[0033] The content of the bacteria belonging to Bifidobacterium longum subsp. infantis in the medicine for improving mental health disorders of the present invention is not particularly limited, and can be appropriately selected based on the daily intake or administration amount according to the dosage form. For example, 6 ~1×10 12 cfu / g or 1×10 6 ~1×10 12 cfu / mL is preferred, and 1×10 7 ~1×10 11 cfu / g or 1×10 7 ~1×10 11 More preferably, it is 1×10 cfu / mL. 8 ~1×10 10 cfu / g or 1×10 8 ~1×10 10 It is more preferable to use cfu / mL. The unit cfu is an abbreviation of colony forming units. When the bacteria is killed, cfu / g or cfu / mL can be replaced with individual cells / g or individual cells / mL.
[0034] The dosage of the medicament for improving mental health disorders of the present invention is 1×10 in terms of the amount of bacteria belonging to Bifidobacterium longum subsp. infantis per kg of body weight of the subject. 6 ~1×10 12 cfu / day is preferred, 1×10 7 ~1×10 11 cfu / day is more preferable, 1×10 8 ~1×10 10 cfu / day is more preferred. When the bacteria is killed, cfu / day can be replaced with individual cells / day. The method of administration of the medicament for improving mental health disorders of the present invention may be oral administration or parenteral administration. In addition, the medicament for improving mental health disorders of the present invention may be administered once a day or in multiple divided doses.
[0035] As the pharmaceutical carrier, various organic or inorganic carriers can be used depending on the dosage form. Examples of carriers in the case of solid preparations include excipients, binders, disintegrants, lubricants, stabilizers, flavoring agents, etc.
[0036] Examples of excipients include sugar derivatives such as lactose, sucrose, glucose, mannitol, and sorbitol; starch derivatives such as corn starch, potato starch, α-starch, dextrin, and carboxymethyl starch; cellulose derivatives such as crystalline cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, carboxymethyl cellulose, and calcium carboxymethyl cellulose; gum arabic; dextran; pullulan; silicate derivatives such as light anhydrous silicic acid, synthetic aluminum silicate, and magnesium aluminometasilicate; phosphate derivatives such as calcium phosphate; carbonate derivatives such as calcium carbonate; and sulfate derivatives such as calcium sulfate.
[0037] Examples of binders include gelatin, polyvinylpyrrolidone, macrogol, and the like, in addition to the above-mentioned excipients.
[0038] Examples of disintegrants include the above-mentioned excipients, as well as chemically modified starch or cellulose derivatives such as croscarmellose sodium, sodium carboxymethyl starch, and crosslinked polyvinylpyrrolidone.
[0039] Examples of lubricants include talc; stearic acid; metal stearates such as calcium stearate and magnesium stearate; colloidal silica; waxes such as pea gum and geranium stearate; boric acid; glycol; carboxylic acids such as fumaric acid and adipic acid; sodium carboxylates such as sodium benzoate; sulfates such as sodium sulfate; leucine; lauryl sulfates such as sodium lauryl sulfate and magnesium lauryl sulfate; silicic acids such as silicic anhydride and silicic acid hydrate; starch derivatives, and the like.
[0040] Examples of the stabilizer include paraoxybenzoic acid esters such as methylparaben and propylparaben; alcohols such as chlorobutanol, benzyl alcohol, and phenylethyl alcohol; benzalkonium chloride; acetic anhydride; and sorbic acid.
[0041] Examples of the flavoring agent include sweeteners, acidulants, fragrances, etc. In the case of a liquid preparation for oral administration, examples of the carrier used include solvents such as water, flavoring agents, etc.
[0042] The pharmaceutical for improving mental health disorders of the present invention can be applied to diseases that can be alleviated, prevented, or treated by improving mental health disorders. Diseases that can be alleviated, prevented, or treated by improving mental health disorders are diseases whose symptoms can be determined to be alleviated or improved when the scores of "Mental Health (MH)" and / or "Mental Health Score (MCS)" in the SF-36 are increased. Specific examples of such diseases include post-traumatic stress disorder (PTSD), dripping faucet syndrome, alcoholism, dissociative disorder, obsessive-compulsive disorder, autonomic nervous system imbalance, adjustment disorder, phobia, social phobia, agoraphobia, affective disorder, tic disorder, personality disorder, developmental disorder, etc. Among the above-mentioned diseases, the present invention is particularly suitable for diseases caused by natural disasters.
[0043] The pharmaceutical composition for improving mental health disorders of the present invention may be administered alone or in combination with other pharmaceutical compositions, such as other pharmaceutical compositions for improving mental health disorders, antipsychotics, anti-anxiety agents, hallucinogens, mood stabilizers, psychostimulants, sleeping pills, etc.
[0044] <Food and drink composition> The food and beverage composition for improving mental health disorders of the present invention may be produced by adding bacteria belonging to Bifidobacterium longum subsp. infantis to known food and beverage products, or a new food and beverage composition may be produced by mixing the bacteria into the raw materials of the food and beverage products.
[0045] The food and beverage compositions for improving mental health disorders of the present invention may be in any form, such as liquid, paste, solid, powder, etc., and may include, in addition to tablet confectioneries, liquid foods, feed (including for pets), for example, flour products, instant foods, processed agricultural products, processed marine products, processed livestock products, milk and dairy products, oils and fats, basic seasonings, complex seasonings and foods, frozen foods, confectioneries, beverages, and other commercially available products.
[0046] Furthermore, the food and drink composition for improving mental health disorders defined in the present invention can be provided and sold as a food or drink labeled for health uses such as improving mental health disorders. The act of "indicating" includes all acts aimed at informing consumers of the aforementioned uses, and any expression that can recall or infer the aforementioned uses falls under the category of "indicating" in the present invention, regardless of the purpose of the indication, the content of the indication, the object or medium on which it is displayed, etc.
[0047] Furthermore, it is preferable that the "labeling" be done in an expression that allows consumers to directly recognize the above-mentioned uses.Specific examples include the act of transferring, delivering, displaying for the purpose of transferring or delivering, or importing food and beverage products or product packaging on which the above-mentioned uses are written, displaying or distributing advertisements, price lists, or transaction documents related to the products and writing the above-mentioned uses in information containing the above-mentioned uses and providing them by electromagnetic means (such as the Internet), etc.
[0048] On the other hand, the content of the labeling is preferably a labeling approved by the government etc. (for example, a labeling approved based on various systems established by the government and made in a manner based on such approval, etc.) In addition, it is preferable that such a labeling content is affixed to the packaging, containers, catalogs, pamphlets, POP and other sales site promotional materials, other documents, etc.
[0049] In addition, "labeling" also includes labeling as health food, functional food, enteral nutrition food, special purpose food, health functional food, food for specified health uses, nutrient functional food, functional food, functional labeling food, medical drug, etc. Among these, in particular, labeling approved by the Consumer Affairs Agency, for example, labeling approved under the system related to food for specified health uses, nutrient functional food, or functional labeling food, or a similar system, etc., can be mentioned. Specifically, labeling as food for specified health uses, labeling as food for conditional specified health uses, labeling that affects the structure or function of the body, labeling for reducing disease risk, labeling of functionality based on scientific evidence, etc., can be mentioned, and more specifically, labeling as food for specified health uses (especially labeling of health uses) and similar labeling as specified in the Cabinet Office Ordinance on the Permission of Labeling for Special Uses Prescribed in the Health Promotion Act (Cabinet Office Ordinance No. 57 of August 31, 2009) are typical examples.
[0050] In addition, the content of the bacteria belonging to Bifidobacterium longum subsp. infantis in the food and drink composition for improving mental health disorders of the present invention is not particularly limited and can be appropriately selected based on the daily intake amount. For example, the content of the bacteria belonging to Bifidobacterium longum subsp. infantis in the food and drink composition for improving mental health disorders of the present invention is not particularly limited and can be appropriately selected based on the daily intake amount. 6 ~1×10 12 cfu / g or 1×10 6 ~1×10 12 cfu / mL is preferred, and 1×10 7 ~1×10 11 cfu / g or 1×10 7 ~1×10 11 More preferably, it is 1×10 cfu / mL. 8 ~1×10 10 cfu / g or 1×10 8 ~1×10 10It is more preferable to use cfu / mL. If the bacteria is killed, cfu / g or cfu / mL can be replaced with individual cells / g or individual cells / mL.
[0051] The intake amount of the food and drink composition for improving mental health disorders of the present invention is 1×10 as the amount of bacteria belonging to Bifidobacterium longum subsp. infantis per kg of body weight of the subject. 6 ~1×10 12 cfu / day is preferred, 1×10 7 ~1×10 11 cfu / day is more preferable, 1×10 8 ~1×10 10 More preferably, it is cfu / day. If the bacteria is killed, cfu / day can be replaced with individual cells / day.
[0052] Furthermore, the present invention can also employ the following configuration. [1] An agent for improving mental health disorders, a composition for improving mental health disorders, or a food or beverage composition for improving mental health disorders, comprising as an active ingredient a bacterium belonging to Bifidobacterium longum subsp. infantis. [2] The agent or composition for improving mental health disorders, or the food or beverage composition for improving mental health disorders described in [1], wherein the bacterium is Bifidobacterium longum subsp. infantis BCCM LMG23728. [3] The mental health disorder improving agent or composition for improving a mental health disorder, or the food and beverage composition for improving a mental health disorder, according to [1] or [2], wherein the mental health disorder is assessed by SF-36. [4] The mental health deficiency improving agent or composition for improving mental health deficiency, or food and beverage composition for improving mental health deficiency, described in [3], wherein the mental health deficiency is a state in which the mental health (MH) and / or mental health status (MCS) score is low. [5] An agent or composition for improving mental health disorders, or a food or beverage composition for improving mental health disorders, according to any one of [1] to [4], wherein the improvement of mental health disorders is the alleviation, improvement or elimination of a nervous psychological state, depressed mood, or gloomy mood, or the improvement of a calm or happy mood. [6] Use of a bacterium belonging to Bifidobacterium longum subsp. infantis in the manufacture of a composition for improving mental health disorders or a medicine for improving mental health disorders. [7] Use of bacteria belonging to Bifidobacterium longum subsp. infantis for improving mental health disorders. [8] A bacterium belonging to Bifidobacterium longum subsp. infantis that is used to improve mental health disorders. [9] A method for improving mental health disorders, comprising the step of administering to a subject a bacterium belonging to Bifidobacterium longum subsp. infantis, or an agent for improving mental health disorders or a composition for improving mental health disorders described in any of [1] to [5], or a food or beverage composition for improving mental health disorders.
[10] A method for alleviating, preventing or treating a disease that can be alleviated, prevented or treated by improving mental health disorders, comprising the step of administering to a subject a bacterium belonging to Bifidobacterium longum subsp. infantis, or an agent for improving mental health disorders or a composition for improving mental health disorders described in any of [1] to [5], or a food or beverage composition for improving mental health disorders.
[11] An agent for adjusting the composition ratio of intestinal bacteria in intestinal flora or a composition for adjusting the composition ratio of intestinal bacteria, an agent for improving the composition ratio of intestinal bacteria in intestinal flora or a composition for improving the composition ratio of intestinal bacteria, or a food or beverage composition for adjusting the composition ratio of intestinal bacteria in intestinal flora or a food or beverage composition for improving the composition ratio of intestinal bacteria in intestinal flora, which comprises a bacterium belonging to Bifidobacterium longum subsp. infantis as an active ingredient.
[12] An agent for adjusting the composition ratio of intestinal bacteria in intestinal flora or a composition for adjusting the composition ratio of intestinal bacteria, an agent for improving the composition ratio of intestinal bacteria in intestinal flora or a composition for improving the composition ratio of intestinal bacteria, or a food and beverage composition for adjusting the composition ratio of intestinal bacteria in intestinal flora or a food and beverage composition for improving the composition ratio of intestinal bacteria in intestinal flora, as described in
[11] , wherein the intestinal bacteria ratio is the composition ratio of bacteria belonging to the phylum Firmicutes to bacteria belonging to the phylum Bacteroidetes in the intestinal flora.
[13] An agent for adjusting the composition ratio of intestinal bacteria in intestinal flora or a composition for adjusting the composition ratio of intestinal bacteria in intestinal flora described in
[11] or
[12] , which reduces the composition ratio of bacteria belonging to the phylum Firmicutes relative to bacteria belonging to the phylum Bacteroidetes in the intestinal flora. An agent for improving the composition ratio of intestinal bacteria in intestinal flora or a composition for improving the composition ratio of intestinal bacteria in intestinal flora, or a food and beverage composition for adjusting the composition ratio of intestinal bacteria in intestinal flora or a food and beverage composition for improving the composition ratio of intestinal bacteria in intestinal flora.
[14] An agent for adjusting the composition ratio of intestinal bacteria in intestinal flora or a composition for adjusting the composition ratio of intestinal bacteria in intestinal flora, an agent for improving the composition ratio of intestinal bacteria in intestinal flora or a composition for improving the composition ratio of intestinal bacteria in intestinal flora, or a food and beverage composition for adjusting the composition ratio of intestinal bacteria in intestinal flora or a food and beverage composition for improving the composition ratio of intestinal bacteria in intestinal flora, as described in any of
[11] to
[13] , which increases the occupancy rate of bacteria belonging to the Bacteroidetes phylum in the intestinal flora.
[15] An agent for adjusting the composition ratio of intestinal bacteria in intestinal flora or a composition for adjusting the composition ratio of intestinal bacteria in intestinal flora, an agent for improving the composition ratio of intestinal bacteria in intestinal flora or a composition for improving the composition ratio of intestinal bacteria in intestinal flora, or a food and beverage composition for adjusting the composition ratio of intestinal bacteria in intestinal flora or a food and beverage composition for improving the composition ratio of intestinal bacteria in intestinal flora, according to any of
[11] to
[14] , which reduces the occupancy rate of bacteria belonging to the Firmicutes phylum in the intestinal flora.
[16] An agent for adjusting the composition ratio of intestinal bacteria in intestinal flora or a composition for adjusting the composition ratio of intestinal bacteria, an agent for improving the composition ratio of intestinal bacteria in intestinal flora or a composition for improving the composition ratio of intestinal bacteria, or a food or beverage composition for adjusting the composition ratio of intestinal bacteria in intestinal flora or a food or beverage composition for improving the composition ratio of intestinal bacteria in intestinal flora, according to any of
[11] to
[15] , wherein the bacterium belonging to Bifidobacterium longum subsp. infantis is BCCM LMG23728. EXAMPLES
[0053] The present invention will be described in more detail below using examples, but the present invention is not limited to these examples.
[0054] [Test Example 1] (1) Sample preparation The culture medium of Bifidobacterium longum subsp. infantis BCCM LMG23728 was concentrated, freeze-dried, and mixed with maltodextrin (Matsutani Chemical Co., Ltd.) to prepare a bacterial powder containing Bifidobacterium longum subsp. infantis BCCM LMG23728. 1.0 g of the bacterial powder was divided into aluminum bags, and each bag contained 1.0 × 10 9 Individual packets containing cfu of Bifidobacterium longum subsp. infantis BCCM LMG23728 were obtained.
[0055] (2) Oral ingestion test A test was conducted to confirm the effect of the mental health disorder improving agent of the present invention on 31 victims of the flood that occurred in the Kelantan region of Malaysia. Of the 31 subjects, 11 were classified as the intake group, and the bacterial powder produced in the above "(1) Sample Preparation" was taken once a day for three months at a rate of one packet per day. Meanwhile, 20 of the 31 subjects other than the intake group were classified as the non-intake group (control group), and the intake group and non-intake group were subjected to QOL evaluation using SF-36 twice in total, on the day the test started (first time) and on the day the test ended three months after the test started (second time). Based on the methodology used in "The Japanese Journal of Low Back Pain, Vol. 8, No. 1, pp. 38-43, 2002," the eight items of physical function (PF), role functioning (physical) (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role functioning (mental) (RE) and mental health (MH) were classified into two categories: physical aspects and mental aspects. Physical health score (PCS) and mental health score (MCS) were calculated, and statistically significant differences were examined using the Mann-Whitney U test.
[0056] (3) Results The scores on the final day of the study and the score change before and after the study (the score on the final day of the study minus the score on the first day of the study) were calculated for the eight items of the SF-36: physical functioning (PF), role functioning (physical) (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role functioning (mental) (RE) and mental health (MH), as well as for the physical health status (PCS) and mental health status (MCS). The results are shown in Table 1.
[0057] [Table 1]
[0058] Of the eight items in the SF-36, seven items, namely physical functioning (PF), role functioning (RP), bodily pain (BP), general well-being (GH), vitality (VT), social functioning (SF), and role functioning (RE), as well as physical health status (PCS), showed no significant differences between the non-ingestion group and the intake group in either the scores on the final day of the test or the score change before and after the test. On the other hand, the score change before and after the test for mental health (MH) and mental health status (MCS) is shown in Figures 1 and 2, respectively, and the intake group showed significantly larger values than the non-ingestion group. Specifically, the score change (average value) for mental health (MH) increased by 17.27 in the intake group, while it was -13.40 in the non-ingestion group, resulting in a decrease in the score, contrary to the intake group. Similarly, the mean change in mental health score (MCS) increased by 7.92 in the intake group, while it was -4.44 in the non-intake group, meaning that the non-intake group's score decreased compared to the intake group. In addition, the scores for mental health (MH) and mental health status (MCS) on the final day of the study are shown in Figures 3 and 4, respectively, and were significantly higher in the intake group compared to the non-intake group. Specifically, the mental health (MH) score (average) on the final day of the study was 80.4 in the intake group, while it was 67.0 in the non-intake group, meaning that the non-intake group had a score more than 10 points lower than the intake group. Furthermore, the mental health (MCS) score (average) on the final day of the study was 56.8 in the intake group, while it was 49.8 in the non-intake group, meaning that the non-intake group had a score 7 points lower than the intake group.
[0059] The results of this study revealed that taking Bifidobacterium longum subsp. infantis BCCM LMG23728 powder increased the mental health (MH) and mental health score (MCS) scores in the SF-36. In mental disorders such as depression, the scores of the eight items in the SF-36 are generally low, so it is assumed that when mental disorders such as depression improve, the SF-36 scores will generally increase. However, in this study, only the mental health (MH) and mental health score (MCS) scores in the SF-36 were significantly higher. In other words, it was confirmed that taking Bifidobacterium longum subsp. infantis BCCM LMG23728 powder increased the mental health (MH) and mental health score (MCS) scores, improving mental health problems.
[0060] [Test Example 2] (1) Intestinal flora analysis In order to examine the relationship between the mental health deficiency improving effect confirmed in Test Example 1 and the intestinal flora (brain-gut correlation), the intestinal flora was analyzed in the subjects of Test Example 1. Specifically, stool samples were collected from the non-ingestion group and intake group of Test Example 1 on the final day of the study, and the collected samples were suspended in RNA-Later (manufactured by Thermo Fisher Scientific) and stored at room temperature. From the solution, the DNA of bacteria contained in the stool was extracted using a Qiagen stool DNA extraction kit (manufactured by Qiagen) to obtain a DNA solution.
[0061] Next, a first primer set for amplifying the third and fourth variable regions of the bacterial 16S rRNA gene, Tru357F (5'-CGCTCTTCCGATCTCTGTACGGRAGGCAGCAG-3'; sequence number 1) and Tru806R (5'-CGCTCTTCCGATCTGACGGACTACHVGGGTWTCTAAT-3'; sequence number 2), and a second primer set required for analysis using a next-generation sequencer Miseq (manufactured by Illumina), Fwd (5'-AATGATACGGCGACCACCGAGATCTACACNNNNNNNNACACTCTTTCCCTACACGACGCTCTTCCGATCTCTG-3'; sequence number 3) and Rev (5'-CAAGCAGAAGACGGCATACGAGATNNNNNNNNGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTGAC-3'; sequence number 4), were designed, and the primers were synthesized using the oligo primer creation service of Life Technologies. In addition, "N" in the base sequence is a barcode sequence consisting of any base.
[0062] A reaction solution containing the DNA solution and the first primer set and having a total volume of 25 μl was prepared using Takara Extaq HS kit (manufactured by Takara Bio Inc.) The nucleic acid amplification reaction was carried out using a thermal cycler, with one cycle of 94°C-3 minutes, 94°C-30 seconds, 50°C-30 seconds, and 72°C-30 seconds repeated 30 times, followed by 72°C-5 minutes, for PCR reaction. Next, PCR reaction was carried out under the same conditions as when the 1st primer was used, except that 1 μl of the obtained PCR product was used as a template, the 2nd primer set was used, and the number of cycles was set to 8. The obtained PCR product was purified using a QIA quick 96 PCR Purification kit (Qiagen). PCR products derived from multiple samples were mixed at the same concentration and subjected to Miseq v3 Reagent kit (Illumina), and sequence analysis was performed using Miseq.
[0063] From the paired-end sequences obtained by sequence analysis, sequences corresponding to Reference Consortium human build 38 and PhiX 174 were detected using bowtie-2 (ver. 2-2.2.4), and the detected sequences were excluded from the analysis. Then, sequences with a PHRED quality score of 17 or less were trimmed, and sequences shorter than 150 bases or with an average PHRED quality score of 25 or less were deleted. Then, the paired-end sequences were joined using fastq-join (ver. 1.1.2-537), and chimeric sequences were removed using USEARCH (ver. 5.2.32) and the gold database (http: / / drive5.com / otupipe / gold.tz) to obtain the sequences to be used in the analysis. For the analysis of the bacterial groups, the open-reference OTU (Operational Taxonomy Unit) picking method in Qiime software (version 1.8.0) and the database: Greengenes database13_8 were used to define OTUs as sequences with 97% homology. The composition ratio of enterobacteria was analyzed by performing a homology search of representative sequences of each OTU against the Greengenes database 13_8.
[0064] (2) Results As shown in Figures 5, 6 and 7, the occupancy rate of bacteria belonging to the Bacteroidetes phylum in the intestinal flora of the intake group after the end of the test was 58% on average, which was significantly higher than the average occupancy rate of bacteria belonging to the Bacteroidetes phylum in the non-intake group (45%) (Figure 5). In addition, the occupancy rate of bacteria belonging to the Firmicutes phylum in the intestinal flora of the intake group after the end of the test was 24% on average, which was significantly lower than the average occupancy rate of bacteria belonging to the Firmicutes phylum in the non-intake group (39%) (Figure 6). Furthermore, the composition ratio of the above two bacteria in the intestinal flora of the intake group after the end of the test (bacteria belonging to the Firmicutes phylum / bacteroidetes phylum) was 0.44 on average, which was significantly lower than the average composition ratio of the above two bacteria in the non-intake group (1.08) (Figure 7). Note that the significant difference was examined using the Mann-Whitney U test.
[0065] Furthermore, the Spearman correlation between the mental health score (MCS) (Figure 4) after the end of the test in Test Example 1 and the above-mentioned composition ratio in the intestinal flora (Figure 7) was analyzed using IBM SPSS Statistics (Ver. 22). As a result, as shown in Figure 8, a significant negative correlation was observed between the two. In other words, a correlation was observed between the increase in mental health score (MCS) and the decrease in the above-mentioned composition ratio in the intestinal flora due to the intake of Bifidobacterium longum subsp. infantis BCCM LMG23728. Therefore, it was suggested that Bifidobacterium longum subsp. infantis BCCM LMG23728 improves mental health problems by reducing the above-mentioned composition ratio in the intestinal flora of the subjects who took it.
[0066] [Production Example 1] Bifidobacterium longum subsp. infantis BCCM LMG23728 is added to 3 mL of MRS liquid medium and cultured anaerobically at 37°C for 16 hours. The culture medium is concentrated and freeze-dried to obtain powder of the bacteria. The powder is mixed with excipients and other ingredients as appropriate to form tablets. The tablets are then packed into a container with a bacterial intake of 1 x 10 6 ~1×1012 The animals are fed daily for 3 months to achieve cfu / kg body weight / day. Taking these tablets is expected to have the effect of improving mental health problems, as well as the effect of adjusting and improving the composition ratio of intestinal flora.
[0067] [Production Example 2] Bifidobacterium longum subsp. infantis BCCM LMG23728 is added to 3 mL of MRS liquid medium and cultured anaerobically at 37°C for 16 hours. The culture medium is concentrated and freeze-dried to obtain a powder of the bacteria. The powder is added to the fermented milk raw material to obtain fermented milk. The fermented milk is cultured at a concentration of 1×10 6 ~1×10 12 Feed daily for at least 3 months to achieve cfu / kg body weight / day. Ingestion of this fermented milk is expected to have the effect of improving mental health problems, as well as the effect of adjusting and improving the composition ratio of the intestinal flora.
Claims
1. A composition for improving mental health disorders, comprising Bifidobacterium longum subsp. infantis M-63 (NITE BP-02623) as an active ingredient, The composition, wherein the mental health impairment is mental health (MH) and / or mental health status (MCS) as assessed by SF-36.
2. 2. The method of claim 1, wherein the mental health problem is a mental health (MH) score of 70 or less and / or a mental health status (MCS) score of 50 or less. A composition for improving general health problems.
3. A food and drink composition for improving mental health disorders, comprising Bifidobacterium longum subsp. infantis M-63 (NITE BP-02623) as an active ingredient, The food and beverage composition, wherein the mental health disorder is mental health (MH) and / or mental health status (MCS) assessed by SF-36.
4. 4. The method of claim 3, wherein the mental health problem is a mental health (MH) score of 70 or less and / or a mental health status (MCS) score of 50 or less. Food and drink compositions for improving health problems.
Citation Information
Patent Citations
Probiotic for the treatment of atypical depression and other disorders characterized by hypothalamic-pituitary-adrenal axis hypersensitivity
JP2006525313A
Method for measuring viable cell count
JP2012223134A
Medicine for improving anxiety and / or hyperactivity
JP2013119546A
Milk-based nutritional compositions containing lactoferrin and uses thereof
JP2016503025A
State of mind improvement agent
JP2010209022A
